SolasCure's Aurase Wound Gel Demonstrates 22x Faster Debridement in Phase II Chronic Wound Trial
Key Insights
SolasCure (search) completed its Phase II CLEANVLU2 trial showing Aurase Wound Gel (search) achieved 22 times faster debridement and 7 times faster healing compared to standard care in chronic venous leg ulcers.
The treatment demonstrated dual mechanism of action through tarumase (search), which removes necrotic tissue while activating PAR2 receptors to initiate tissue repair pathways from first application.
After 26 days, patients achieved 65% debridement versus 9% in control group and 58% wound area reduction versus 15% in control, with excellent safety profile.
SolasCure (search) has successfully completed its Phase II CLEANVLU2 clinical trial, demonstrating that Aurase Wound Gel (search) (AWG) significantly accelerates chronic wound healing compared to standard care. The biotechnology company reported that patients with treatment-resistant venous leg ulcers experienced 22 times faster debridement and seven times faster healing rates when treated with higher concentrations of the investigational therapy.
Clinical Trial Results Show Dramatic Improvement
The CLEANVLU2 study evaluated efficacy and dose response in patients with chronic venous leg ulcers, building on the earlier Phase IIa CLEANVLU1 trial that established proof of concept and demonstrated a strong safety profile. After 26 days of treatment, AWG achieved 65% debridement compared to 9% in the control group (p=0.005) and 58% wound area reduction versus 15% in control (p=0.022).
The control group received standard care consisting of hydrogel in combination with advanced moist wound healing dressings and compression bandaging systems. The statistically significant results provide clinical validation of AWG's ability to deliver continuous enzymatic debridement while simultaneously activating wound healing processes.
Dual Mechanism of Action Drives Enhanced Healing
AWG combines a proprietary hydrogel formulation with the active pharmaceutical ingredient tarumase (search). The clinical data revealed a dual mechanism of action where tarumase not only continuously removes necrotic tissue but also activates PAR2 receptors involved in tissue repair, initiating healing pathways from the first application.
This dual approach addresses a key limitation in current chronic wound therapies, which primarily focus on wound bed preparation rather than directly stimulating the biological processes required for healing. The treatment maintained an excellent safety profile throughout the study, caused no additional pain to patients, and was associated with improvements in quality of life across physical, psychological, and daily living measures.
Addressing Significant Unmet Medical Need
Chronic wounds affect millions of patients worldwide and place a substantial burden on healthcare systems. The clinical milestone highlights AWG's potential to address wound bed preparation, debridement, and sustained healing within a single therapeutic approach.
Rob Kirsner, M.D., PhD, Head of Medical Advisory Board at SolasCure (search) and Chairman and Harvey Blank Professor of Dermatology at the University of Miami, commented: "These Phase II results represent a highly encouraging advance in the treatment of chronic wounds. From a clinical perspective, the data demonstrate very effective debridement alongside meaningful activation of the biological processes leading to healing."
Next Steps and Development Plans
The successful completion of CLEANVLU2 supports advancement to the next phase of development and positions SolasCure (search) for further engagement with investors and strategic partners. Full clinical data from the trial will be submitted for peer-reviewed publication, providing additional scientific validation of the treatment approach.
The results represent a significant step forward in chronic wound care, potentially offering patients a more effective treatment option that combines multiple therapeutic benefits in a single application.